http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이지훈,박재범,박단비,허증수,임정옥,Lee, Jihoon,Park, Jaebum,Park, Danbi,Huh, Jeung Soo,Lim, Jeong Ok 한국재료학회 2021 한국재료학회지 Vol.31 No.7
Graphene, a new material with various advantageous properties, has been actively used in various fields in recent years. Applications of graphene oxide are increasing in combination with other materials due to the different properties of graphene oxide, depending on the number of single and multiple layers of graphene. In this study, single-layer graphene oxide and multi-layer graphene oxide are spray coated on polystyrene, and the physicochemical properties of the coated surfaces are characterized using SEM, Raman spectroscopy, AFM, UV-Vis spectrophotometry, and contact angle measurements. In single-layer graphene oxide, particles of 20 ㎛ are observed, whereas a 2D peak is less often observed, and the difference in surface height increases according to the amount of graphene oxide. Adhesion increases with an increase in graphene oxide up to 0.375 mg, but decreases at 0.75 mg. In multi-layer graphene oxide, particles of 5 ㎛ are observed, as well as a 2D peak. According to the amount of graphene oxide, the height difference of the surface increases and the adhesive strength decreases. Both materials are hydrophilic, but single-layer graphene oxide has a hydrophilicity higher than that of multi-layer graphene oxide. We believe that multi-layer graphene oxide and single-layer graphene oxide can be implemented based on the characteristics that make them suitable for application.
이동 컨텐츠 중심 네트워크에서의 효율적인 계층적 이동성 관리 방안
이지훈(Jihoon Lee),이주용(Juyong Lee) 한국산학기술학회 2018 한국산학기술학회논문지 Vol.19 No.2
본 사용자들이 언제 어디서든 다양한 컨텐츠를 생성하고 공유함에 따라, IP 주소 기반의 인터넷 전송 기술을 대체하기 위한 컨텐츠 이름을 식별자로 사용하는 컨텐츠 중심 네트워킹과 같은 새로운 네트워킹 기술들이 주목받고 있다. 그러나, 현재 CCN 기술은 사용자 이동성, 특히 이동 컨텐츠 소스의 이동성에 대해 거의 고려하지 않고 있다. 따라서, 이동 컨텐츠 소스의 이동으로 인해 컨텐츠 전달 서비스의 단절, 서비스 지연 증가와 같은 문제가 발생한다. 이러한 문제를 해결하기 위해, 터널링 기반 이동성 방안이 제안되었으나, 이동이 발생할 때마다 위치 정보 업데이트 과정이 요구된다. 따라서, 많은 제어 오버헤드가 발생하고, 핸드오프 동안 높은 패킷 손실롤 인해 재전송에 따른 서비스 지연과 전체 네트워크의 성능 저하를 문제를 야기한다. 이에, 본 논문에서는 CCN향 계층적 이동성 관리 방안을 제시하여 제어 메시지의 발생을 제한하여 핸드오프 지연을 감소시켰다. 성능 분석을 통해 제안 방안이 제어 오버헤드 감소에 따른 네트워크 확장성을 제공함으로 확인하였다. As individuals generate and share various content anytime and anywhere, new networking architectures, such as content-centric networking (CCN) using the content name as a packet identifier, have been in the spotlight recently. However, the current CCN hardly takes into account node mobility problems, especially the mobility of content sources. The movement of content sources causes long delivery latency and long service disruptions. To solve that, the tunneling-based redirection scheme was proposed. However, the tunneling-based scheme requires a location-update procedure whenever the network changes, which creates many control messages and causes long latency. So, this paper presents hierarchical mobility management of mobile CCN to reduce the number of control messages and handoff latency. Performance evaluation shows that the proposed scheme can provide low control overhead, which results in network scalability.
인체세포ㆍ조직이용 의료제품 등의 규제에 관한 국내외 규정 비교 및 안전관리 개선방안 연구
이지훈(Jihoon Lee),최수경(Soo Kyung Choi),김주희(Juhui Gim),박미영(Miyoung Park),박수현(Soo Hyun Park),최진희(Jinhee Choi),임화경(Hwakyung Lim),노혜민(Hyemin Noh),이윤희(Yun hee Lee),윤재석(Jaesuk Yun) 대한약학회 2018 약학회지 Vol.62 No.3
Over the past several decades, human-derived cells, tissues, and cell- and tissue-based therapies have contributed to essential body function regeneration in the absence of effective alternative medicine substitute. This study reviewed strength and weakness of the regulation related to human-derived cells, tissues based pharmaceutical products compared to the US regulation, and suggested points for improvement classified into three categories. First, it is necessary to supplement regulations and guidelines on donor eligibility for pharmaceutical products. Second, there is a need to integrate regulations related to classify pharmaceutical product into biologics, device, and combination products. Finally, there is a need to develop and supplement the traceability of biological traces and the regulations for biological monitoring systems of pharmaceutical products. Collectively, it would be necessary to revise the regulations and the guidelines for the approval, manufacture, management and tracking of human cell/tissue derived pharmaceutical products by collecting opinions from researchers, industry, and clinical health care workers with a systematic long-term goal.